Skip to main content

Table 4 Primary outcome and prognosis.

From: The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

 

Control group (n= 180)

Tα1 (n= 181)

P value

28-day mortality

63 (35.0%)

47 (26.0%)

0.062

In-hospital mortality

71 (39.4%)

52 (28.7%)

0.032

In-ICU mortality

48 (26.7%)

35 (19.3%)

0.098

Duration of ventilation

   

   Median (IQR)

6.0 (2.0-14.0)

7.0 (3.0-13.0)

0.742

ICU stay

   

   Median (IQR)

10.5 (5.0-20.5)

11.0 (7.0-20.0)

0.254

Ventilation-free days*

   

   Median (95% CI)

13.0 (7.0-18.0)

18.0 (15.0-21.0)

0.077

ICU-free days*

   

   Median (95% CI)

5.0 (0.3-10.7)

10.0 (6.8-15.0)

0.235

  1. 'Free days' were calculated as the number of days that the patient was alive and free of given measure (ventilator use and ICU stay) during the 28-day study period. CI, confidence interval; IQR, interquartile range; Tα1, thymosin alpha 1.
Back to article page

Critical Care

ISSN: 1364-8535